Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Floxacillin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : SignaTope GmbH, Germany
Deal Size : Inapplicable
Deal Type : Inapplicable
Flucloxacillin as an Inducer of CYP-enzymes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 12, 2021
Lead Product(s) : Floxacillin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : SignaTope GmbH, Germany
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Floxacillin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Health Research Board, Ireland
Deal Size : Inapplicable
Deal Type : Inapplicable
Penicillin for the Emergency Department Outpatient Treatment of CELLulitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 04, 2016
Lead Product(s) : Floxacillin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Health Research Board, Ireland
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Floxacillin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
Duration of ANtibiotic Therapy for CEllulitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 10, 2014
Lead Product(s) : Floxacillin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable